Efficacy and Safety of AQX-1125 in Unstable COPD

Summary

The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology 2-containing Inositol-5'-Phosphatase 1) pathway.

Timeline

Start

2013-10

Primary completion

2015-07

Completion

2015-12

Drugs

Indications